Anti-Neoplastic Agents Market Report 2026

The anti-neoplastic agents market size has grown strongly in recent years. It will grow from $142.41 billion in 2025 to $156.08 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited treatment options, high reliance on chemotherapy, slow adoption of targeted therapies, manual manufacturing processes, fragmented regulatory frameworks.

The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $227.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rise of precision medicine, growing geriatric population, increased funding for oncology research, adoption of AI in drug discovery, expansion of global oncology care centers. Major trends in the forecast period include personalized cancer therapies, targeted drug delivery systems, immunotherapy integration, oral and injectable formulation innovations, combination therapy development.

The rising number of cancer cases is expected to drive the growth of the antineoplastic agent market in the coming years. Cancer is a group of diseases that can occur in nearly any organ or tissue when abnormal cells grow uncontrollably, breach their normal boundaries, and either spread to other organs or invade surrounding tissues. Antineoplastic agents are vital in cancer treatment as they inhibit cancer cell growth and division through various mechanisms, including DNA damage, disruption of the cell cycle, and interference with essential cellular pathways. For instance, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, equating to over 450 cases per day, with males accounting for approximately 55% of these diagnoses. Therefore, the increasing number of cancer cases is supporting the growth of the antineoplastic agent market.

Major companies in the antineoplastic agent market are focusing on developing innovative solutions such as selective estrogen receptor degraders to more effectively target hormone receptor-driven cancers, improve patient outcomes, and broaden treatment options. Selective estrogen receptor degraders (SERDs) are targeted cancer therapies that bind to estrogen receptors (ER) in cancer cells, block their activity, and promote their degradation, thereby inhibiting ER-driven tumor growth, particularly in estrogen receptor-positive (ER+) breast cancers. For instance, in September 2025, Eli Lilly and Company, a US-based pharmaceutical company, received US FDA approval for Inluriyo (imlunestrant) to treat adults with estrogen receptor-positive (ER+), HER2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. Inluriyo is an oral estrogen receptor antagonist that blocks and degrades estrogen receptors, including mutated ESR1 receptors that drive cancer growth.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer aims to strengthen its oncology portfolio, accelerate the development and commercialization of targeted cancer therapies, expand its biologics capabilities, and enhance long-term revenue growth in the oncology segment. Seagen Inc., a US-based biotechnology company, specializes in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of various cancers.

Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the anti-neoplastic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-neoplastic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-neoplastic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anti-neoplastic agents market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and specialized equipment used in drug manufacturing. This has particularly impacted the alkylating agents and antimetabolites segments in regions like North America and Europe, which rely heavily on global supply chains. While tariffs have increased production costs and slowed market growth in some areas, they have also encouraged local manufacturing investments and innovation in cost-efficient drug production, creating potential long-term benefits for the market.

The anti-neoplastic agents market research report is one of a series of new reports that provides anti-neoplastic agents market statistics, including anti-neoplastic agents industry global market size, regional shares, competitors with a anti-neoplastic agents market share, detailed anti-neoplastic agents market segments, market trends and opportunities, and any further data you may need to thrive in the anti-neoplastic agents industry. This anti-neoplastic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-neoplastic agents are drugs that prevent or destroy abnormal tissue growth, specifically targeting and combating cancer cells in the body. They play a critical role in cancer treatment by interfering with the processes involved in tumor development and progression.

The main categories of anti-neoplastic agents include alkylating agents, antimetabolites, hormones and antagonists, and miscellaneous types. Alkylating agents are chemical compounds that attach alkyl groups to DNA, RNA, and proteins, disrupting their normal functions and interfering with cell replication. These agents are used to treat a variety of cancers, including gastrointestinal cancer, prostate cancer, lung cancer, breast cancer, and others, and are administered by end users such as hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

The anti-neoplastic agents market consists of sales of antitumor antibiotics, microtubule inhibitors and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.